TIL Therapy for Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This study is a phase I clinical trial to investigate the safety and tolerability of NEOG-100
in patients with advanced breast cancer and lung cancer. NEOG-100, an autologous tumor
infiltrating lymphocytes (TILs), is infused intravenously into the patient after
non-myeloablative (NMA) lymphodepletion treatment.